Sagard Healthcare Partners

Sagard Healthcare Partners is a private equity firm specializing in investments within the healthcare sector, particularly in royalties and credit associated with approved and commercialized biopharmaceutical products, diagnostics, and medical devices. The firm aims to accelerate returns on innovation for intellectual property owners while offering investors attractive healthcare exposure that is largely uncorrelated to other asset classes. Sagard Healthcare Partners is led by a team with over a decade of collaborative experience.

The firm's investment strategy is characterized by a flexible mandate encompassing royalty monetization, revenue-interest financing, and traditional credit. This approach allows Sagard Healthcare Partners to tailor investments to each opportunity, directing capital to areas of higher relative value. Their long-term focus enables value maximization for all parties involved in a transaction. As part of the Sagard platform, the firm benefits from strong operational infrastructure, business support, and networks, enabling the team to concentrate on investments that accelerate returns on innovation in the healthcare industry.

Since its inception in December 2019, Sagard Healthcare Partners has invested over $1 billion in capital, acquiring royalties on innovative drugs such as Jemperli, Voquezna, Tibsovo, Hemgenix, and Tyvaso DPI. The firm has also completed nearly $250 million in new royalty and credit investments, including a $250 million revolving credit facility with a syndicate of lenders. This growth underscores Sagard Healthcare Partners' commitment to expanding its portfolio and delivering attractive returns to its investors.